Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013

Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference 
on March 19, 2013 
SAN DIEGO, CA -- (Marketwire) -- 03/12/13 --  Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
has been invited to present at the ROTH Capital Partners 25th Annual
Growth Stock Conference being held on March 17-20, 2013, at The Ritz
Carlton in Dana Point, Calif. 
Lpath President and CEO Scott Pancoast is scheduled to present on
Tuesday, March 19, 2013 at 1:00 p.m. Pacific time, with one-on-one
meetings held throughout the day. He will discuss the company's
pathway to regulatory approval and commercialization of its novel
lipidomics-based therapeutics, as well as its ability to attract
support from financial and strategic partners such as Pfizer, J&J,
Biogen Idec, and Merck-Serono, as well as the NIH and the Department
of Defense. 
The presentation will be webcast live at
http://www.wsw.com/webcast/roth27/lptn/, which will be available for
replay in the investor relations section at www.lpath.com.  
For more information about the conference or to schedule a one-on-one
meeting with Lpath management, please contact your ROTH
representative at 1-800-933-6830 or via e-mail at
oneononerequests@roth.com. 
About ROTH Capital Partners
 ROTH Capital Partners, LLC (ROTH), is a
relationship-driven investment bank focused on serving emerging
growth companies and their investors. As a full-service investment
bank, ROTH provides capital raising, M&A advisory, analytical
research, trading, market-making services and corporate access.
Headquartered in Newport Beach, CA, ROTH is privately-held and
employee owned, and maintains offices throughout the U.S. and Hong
Kong. For more information on ROTH, please visit www.roth.com. 
About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics. The
company's ImmuneY2(TM) drug-discovery engine has the unique ability
to generate monoclonal antibodies that bind to and inhibit bioactive
lipids that contribute to disease. The company is developing three
drug candidates: iSONEP(TM) is in a Phase 2 trial for wet AMD;
ASONEP(TM) is in a Phase 2 trial in Renal Cell Carcinoma patients;
and Lpathomab is a preclinical drug candidate that holds promise in
pain, neurotrauma, and other diseases. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
Tel: (858) 926-3200
spancoast@Lpath.com 
Lpath Investor Relations
Liolios Group, Inc. 
Tel: (949) 574-3860
lptn@liolios.com
Ron Both: ron@liolios.com
Geoffrey Plank: geoffrey@liolios.com 
 
 
Press spacebar to pause and continue. Press esc to stop.